Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 313,400 shares, a growth of 91.7% from the February 29th total of 163,500 shares. Based on an average daily volume of 5,210,000 shares, the short-interest ratio is presently 0.1 days.

Avenue Therapeutics Stock Performance

Shares of NASDAQ:ATXI opened at $0.15 on Thursday. The company has a market capitalization of $6.75 million, a PE ratio of -0.12 and a beta of -0.25. Avenue Therapeutics has a twelve month low of $0.11 and a twelve month high of $1.36. The firm has a 50 day simple moving average of $0.15 and a 200-day simple moving average of $0.28.

Institutional Trading of Avenue Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXI. Renaissance Technologies LLC purchased a new stake in Avenue Therapeutics in the 2nd quarter valued at $34,000. Virtu Financial LLC purchased a new stake in Avenue Therapeutics in the 1st quarter valued at $28,000. Geode Capital Management LLC increased its stake in Avenue Therapeutics by 359.9% in the 2nd quarter. Geode Capital Management LLC now owns 52,571 shares of the company’s stock valued at $60,000 after buying an additional 41,141 shares during the period. Citadel Advisors LLC acquired a new position in Avenue Therapeutics in the 3rd quarter valued at $362,000. Finally, State Street Corp acquired a new position in Avenue Therapeutics in the 1st quarter valued at $36,000. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Maxim Group started coverage on shares of Avenue Therapeutics in a research note on Monday, December 11th. They issued a “buy” rating for the company.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.